Embed Size (px)
Citation preview
Highlights of the Day: <br />LYMPHOMA
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Abstracts
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Diffuse Large B-cell Lymphoma: How can we improve on R-CHOP?
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Slide 4
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Rituximab clearance by age and gender and study design
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Slide 6
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Slide 7
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Diffuse Large B-cell Lymphoma: How can we improve on R-CHOP?
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Synthetic lethality of lenalidomide in ABC-DLBCL and clinical proof of principle
Presented By Sonali Smith at 2014 ASCO Annual Meeting
PFS by GCB vs. non-GCB Subtype* in RCHOP Case-matched Control and R2CHOP Patients
Presented By Sonali Smith at 2014 ASCO Annual Meeting
OS by GCB vs. non-GCB Subtype in RCHOP Case-matched Control and R2CHOP Patients
Presented By Sonali Smith at 2014 ASCO Annual Meeting
PFS by Treatment Type in GCB vs. non-GCB Subtype
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Abstracts
Presented By Sonali Smith at 2014 ASCO Annual Meeting
FL survival is improving for most patients
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Abstract 8502:<br />246 patients with reviewed postinduction PET-CT<br />
Presented By Sonali Smith at 2014 ASCO Annual Meeting
CT & BM based response (IWC 1999 criteria)
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Both PET cut-offs predictive of PFS
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Postinduction PET status (cut-off ≥4) <br />and Overall Survival
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Abstracts
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Mantle Cell Lymphoma 2014
Presented By Sonali Smith at 2014 ASCO Annual Meeting
CHOP ± Rituximab in MCL: <br />Progression-Free Survival
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Approved agents for R/R MCL<br />(Variable intensity of prior Rx among studies)
Presented By Sonali Smith at 2014 ASCO Annual Meeting
LYM-3002: Replace vincristine with bortezomib
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Superior PFS by IRC with VR-CAP vs R-CHOP: 59% improvement
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Peripheral Neuropathy
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Conclusions – Efficacy
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Abstracts
Presented By Sonali Smith at 2014 ASCO Annual Meeting
Take-home points
Presented By Sonali Smith at 2014 ASCO Annual Meeting
